… to evaluate the safety and efficacy of treatment with nivolumab beyond Response Evaluation
… Criteria for receiving nivolumab beyond progression were investigator-assessed clinical …

… Apart from skin and breast cancers, lung cancer is the most commonly diagnosed cancer in
… In this article, we review the pharmacology as well as the safety and efficacy of nivolumab in …

… We evaluated the efficacy and lung toxicity of nivolumab in patients with … efficacy of nivolumab
by measuring the response rate (RR), progression-free survival (PFS) duration, and lung …

… lung cancer based on the results from phase III clinical trials. We evaluated the real-world
efficacy and safety of nivolumab in … identified the clinical characteristics that influence efficacy. …

… Consistent with clinical trials of nivolumab for lung cancer, the most frequent severe irAE in
our study was pneumonitis [3,4,12,28,29]. The overall incidence of pneumonitis (of any grade…

… of nivolumab in patients with PS of 3 or 4 may be different from that in patients with PS of 2.
However, the survival benefit of nivolumab … the efficacy and safety of nivolumab therapy in …

… the efficacy and safety of nivolumab for pretreated patients with non-small cell … nivolumab
affords clinical efficacy and manageable tolerability in patients with non-small cell lung cancers…

… tolerability of nivolumab was confirmed at … efficacy of nivolumab monotherapy as a second-line
treatment in patients with advanced NSCLC [6, 7], and the combination use of nivolumab …

… Nivolumab has recently received regulatory approval as a 2nd-line treatment of non-small
cell lung cancer (NSCLC). The data regarding its effectiveness and safety in real life setting is …

… The most important finding of the current study is that the efficacy of nivolumab as treatment
modality for lung cancer beyond at least one earlier systemic therapy appears to be slightly …